PEDIATRIC HYDROXYUREA PHASE III CLINICAL TRIAL (BABY HUG) FOLLOW-UP STUDY

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 BABY HUG随访研究的目的是为入组BABY HUG治疗研究的镰状细胞贫血婴儿提供结构化随访，该研究是一项使用羟基脲作为治疗的双盲、随机安慰剂对照试验。将对这组儿童的生长、发育和临床状态进行随访，直至2011年12月31日。收集的数据将有助于确定与在早期使用羟基脲治疗儿童相关的长期毒性和非预期风险。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of the BABY HUG Follow-up Study is to provide structured follow-up of sickle cell infants that were enrolled in the BABY HUG Treatment Study, which was a double-blind, randomized placebo-controlled trial using Hydroxyurea as treatment. This group of children will be followed for growth, development and clinical status until December 31, 2011. Data collected will help to determine the long-term toxicities and unexpected risks associated with treating children with Hydroxyurea at an early age.